NeutraKine® IFN beta Monoclonal antibody

NeutraKine® IFN beta Monoclonal Antibody for ELISA, Neutralization

Host / Isotype

Mouse / IgG1


Human and More (2)


ELISA, Neutralization





Cat no : 69013-1-Ig


Fibroblast interferon, IFB, IFF, IFN beta, IFNB, IFNB1, IFN-beta, Interferon beta, interferon, beta 1, fibroblast, NeutraKine® IFN beta


Product Information

69013-1-Ig targets NeutraKine® IFN beta in ELISA, Neutralization applications and shows reactivity with Human samples.

Tested Reactivity Human
Cited Reactivityhuman, mouse
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen human Humankine IFN beta protein HZ-1298
Full Name IFN beta
Gene Symbol IFN beta1
Gene ID (NCBI) 3456
Conjugate Unconjugated
Form Lyophilized Powder
Purification MethodProtein G purification
Storage Buffer Sterile PBS.
Endotoxin<0.1 EU/μg
ReconstitutionThis product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
Stability and StorageLyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Background Information

Interferon beta (IFN beta) is a cytokine that is naturally produced by the immune system in response to biological and chemical stimuli. It signals by binding to the heterodimeric type I IFN receptor composed of the IFNAR1 and IFNAR2 chains, and regulates the expression of a plethora of genes by means of the classical JAK/STAT and other pathways. Interferon beta (IFN beta) has been shown in several clinical trials to have efficacy in multiple sclerosis. Interferon beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.

This antibody can be used to neutralize the bioactivity of IFN beta.



Nat Commun

Ebola virus VP35 hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association.

Authors - Lin Zhu

Cell Rep

Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis

Authors - Xinyue Ma